Zhejiang Xinguang Pharmaceutical Co., Ltd.

SZSE:300519 Stock Report

Market Cap: CN¥1.7b

Zhejiang Xinguang Pharmaceutical Past Earnings Performance

Past criteria checks 1/6

Zhejiang Xinguang Pharmaceutical's earnings have been declining at an average annual rate of -2.4%, while the Pharmaceuticals industry saw earnings growing at 9.2% annually. Revenues have been growing at an average rate of 2.5% per year. Zhejiang Xinguang Pharmaceutical's return on equity is 6.5%, and it has net margins of 20.4%.

Key information

-2.4%

Earnings growth rate

-2.5%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate2.5%
Return on equity6.5%
Net Margin20.4%
Last Earnings Update31 Mar 2024

Recent past performance updates

Recent updates

Zhejiang Xinguang Pharmaceutical (SZSE:300519) Has Announced That Its Dividend Will Be Reduced To CN¥0.40

May 26
Zhejiang Xinguang Pharmaceutical (SZSE:300519) Has Announced That Its Dividend Will Be Reduced To CN¥0.40

Calculating The Intrinsic Value Of Zhejiang Xinguang Pharmaceutical Co., Ltd. (SZSE:300519)

Apr 16
Calculating The Intrinsic Value Of Zhejiang Xinguang Pharmaceutical Co., Ltd. (SZSE:300519)

Zhejiang Xinguang Pharmaceutical Co., Ltd.'s (SZSE:300519) Low P/E No Reason For Excitement

Feb 26
Zhejiang Xinguang Pharmaceutical Co., Ltd.'s (SZSE:300519) Low P/E No Reason For Excitement

Revenue & Expenses Breakdown

How Zhejiang Xinguang Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SZSE:300519 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 24279574415
31 Dec 23270644315
30 Sep 23305784816
30 Jun 23330874916
31 Mar 23342964915
01 Jan 233511095116
30 Sep 223371164816
30 Jun 223321184914
31 Mar 223271184914
01 Jan 223211144914
30 Sep 213171124713
30 Jun 213141104913
31 Mar 213081114713
31 Dec 20283994712
30 Sep 202911004912
30 Jun 20282974612
31 Mar 20277894614
31 Dec 19291944616
30 Sep 19285914319
30 Jun 19283904419
31 Mar 19277884319
31 Dec 18276884418
30 Sep 18292973129
30 Jun 18291963625
31 Mar 183101064322
31 Dec 173111064818
30 Sep 17308110660
30 Jun 17310113670
31 Mar 17306113680
31 Dec 16315119680
30 Sep 16312117660
30 Jun 16312120630
31 Mar 16315120640
31 Dec 15311119630
31 Dec 14292106590
31 Dec 1326872570

Quality Earnings: 300519 has high quality earnings.

Growing Profit Margin: 300519's current net profit margins (20.4%) are lower than last year (28.2%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 300519's earnings have declined by 2.4% per year over the past 5 years.

Accelerating Growth: 300519's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 300519 had negative earnings growth (-41.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-0.8%).


Return on Equity

High ROE: 300519's Return on Equity (6.5%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.